This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
HomeSearch

Menu

Close

SerotypesSerotypesSerotype CoverageSerotype SelectionCase CoverageEfficacyEfficacyInvasive Pneumococcal DiseaseOtitis MediaClinical Trial Results

Clinical Trial
Results

Study DesignImmunogenicitySafety ProfileDosing & Recommendations

Dosing &
Recommendations

DosingAdherenceDisease BurdenDisease BurdenDisease BurdenDisparitiesAccess & SupportAccess &
SupportOrder Prevnar 20®Commercial health plansEventsMaterialsVideosGeneral Inquiries
Prescribing InformationPatient InformationIndications Patient Site
Help protect babies from the serious threat of invasive pneumococcal disease (IPD) and otitis media (OM)1,2IPD can potentially lead to serious illness in young children. Clinical presentations can include2: Meningitis

Streptococcus pneumoniae is the leading cause of bacterial meningitis among children <5 years of age in the US2

Bacteremia

Bacteremia without a known site of infection is the most common invasive clinical presentation of pneumococcal
infection among children age 2 years or younger2

OM is one of the most frequent reasons for pediatric office visits, resulting in more than 10 million annually.2 Pneumococci are a common cause of acute otitis media and are detected in 24% to 31% of middle ear aspirates.2

OM can cause significant disruptions in children’s health:
 

  • A leading cause of ER visits3
  • The most common reason for tympanostomy tube insertion, the most common ambulatory surgery performed on children in the United States4
  • A common reason for antibiotic use in children <5 years of age.5,6 Recent antibiotic use can contribute to risk for resistant infections7
  • A cause of hearing loss or impairment8
Acute otitis media is the most common clinical presentation of pneumococcal disease in young children.2,9Prevnar 20 is the only PCV indicated to help prevent otitis media, covering 7 OM-causing S. pneumoniae serotypes.1,10*

A leading cause of ER visits4,5

A common reason for antibiotic use in children <5 years of age, which can lead to resistance6-9

The most common reason for surgery6

A cause of hearing loss or impairment10

Explore disparities in PCV series completion
See the vaccination equity gap
LoadingDisease Burden Learn about vaccination rate disparities
See the data
ReferencesER=emergency room; PCV=pneumococcal conjugate vaccine.*Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No OM efficacy data are available for serotypes 1, 3, 5, 6A, 7F, 8, 10A, 11A, 12F, 15B, 19A, 22F, or 33F.1References:Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.Gierke R, Wodi AP, Kobayashi M. Pneumococcal disease. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds.
Epidemiology and Prevention of Vaccine-Preventable Diseases. Centers for Disease Control and Prevention.
14th ed. Public Health Foundation; 2021:255-274.Weiss AJ, Jiang HJ. Statistical brief #286: most frequent reasons for emergency department visits, 2018. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality (US). December 2021. Accessed April 14, 2025. https://hcup-us.ahrq.gov/reports/statbriefs/sb286-ED-Frequent-Conditions-2018.pdfRosenfeld RM, Tunkel DE, Schwartz SR, et al. Clinical practice guideline: tympanostomy tubes in children (update). Otolaryngol Head Neck Surg. 2022;166(suppl 1):S1-S55.Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2):10.1128/microbiolspec.VMBF-0016-2015.Kono M, Umar NK, Takeda S, et al. Novel antimicrobial treatment strategy based on drug delivery systems for acute otitis media. Front Pharmacol. 2021;12:640514.Centers for Disease Control and Prevention. Antibiotic-resistant Streptococcus pneumoniae. December 17, 2024. Accessed January 15, 2025. https://www.cdc.gov/pneumococcal/php/drug-resistance/index.htmlSchilder AGM, Chonmaitree T, Cripps AW, et al. Otitis media. Nat Rev Dis Primers. 2016;2(1):16063.Centers for Disease Control and Prevention. Clinical features of pneumococcal disease. February 6, 2024. Accessed April 15, 2025. https://www.cdc.gov/pneumococcal/hcp/clinical-signs/index.html Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine) Prescribing Information. Merck Sharp & Dohme Corp, 2023.
Manufactured by Wyeth Pharmaceuticals LLC.
Marketed by Pfizer Inc.
PP-PNR-USA-2905 © 2025 Pfizer Inc.
All rights reserved. June 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2905
You are now leaving PfizerPro
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
INDICATIONS 
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups, and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and risks
  • In individuals 2, 4, 6, and 12 through 15 months of age vaccinated with a 4-dose schedule, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, decreased appetite, injection site redness, injection site swelling, and fever
  • In individuals 15 months through 17 years of age vaccinated with a single dose, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, fatigue and muscle pain, decreased appetite, injection site swelling and redness, headache, and fever
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). ​​Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.INDICATIONSIndications
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age